2L
NKTR icon

22NW LP’s Nektar Therapeutics NKTR Stock Holding History

22NW LP’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Hold
281,115
– – 18.75% 2
2026
Q1 		$20.2M Sell
281,115
-50,000
-15% -$2.85M 13.86% 2
2025
Q4 		$14M Hold
331,115
– – 5.89% 4
2025
Q3 		$18.8M Buy
331,115
+185,000
+127% +$6.12M 8.88% 4
2025
Q2 		$3.78M Sell
146,115
-2
-0% -$22 2.38% 12
2025
Q1 		$1.49M Hold
146,117
– – 1% 17
2024
Q4 		$2.04M Buy
+146,117
New +$2.58M 1.29% 13

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

22NW LP's NKTR Position: Q2 2026 in Review

22NW LP held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 281,115 shares worth $19.6M. The position accounts for 18.75% of the portfolio, ranked #2.

22NW LP first reported a position in NKTR in Q4 2024 and has held it in 7 quarters since. The position peaked at $20.2M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • 22NW LP held 281,115 shares of Nektar Therapeutics worth $19.6M as of Q2 2026.
  • 22NW LP left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up 18.75% of 22NW LP's portfolio in Q2 2026, its #2 holding.
  • 22NW LP first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 22NW LP's Nektar Therapeutics position peaked at $20.2M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on 22NW LP's 13F filing for Q2 2026, filed 14 Aug 2026.